5S9-17302-16691
3 vaccinations
1 coded response
30 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 26-30
- ZIP prefix
- 104 / NY
- Registered
- 2021-07-31
- Relationship
- Self
- Race
- Black or African American
- Ethnicity
- N/A
Timeline
-
2021-07-31
Registered in v-safe
-
2021-07-31
Dose 1 — Pfizer-BioNTech
- 2021-08-02
- 2021-08-03
- 2021-08-05
- 2021-08-06
- 2021-08-07
- 2021-08-14
-
2021-08-21
Dose 2 — Pfizer-BioNTech
- 2021-08-21
- 2021-08-22
- 2021-08-23
- 2021-08-24
- 2021-08-25
- 2021-08-26
-
2021-08-27
Health check-in — days 1–6 daily, dose 2Feeling: Poor · Fatigue or tiredness, Nausea · Be unable to work or attend school, Be unable to do your normal daily activitiesAdult check-in
- 2021-08-28
- 2021-09-04
- 2021-09-11
- 2021-09-18
- 2021-09-27
- 2021-10-02
-
2022-02-16
Dose 3 — Pfizer-BioNTech
- 2022-02-19
-
2022-02-19
Survey response — days 1–6 daily, dose 3MedDRA: No adverse event — Feeling: Good · DiarrheaFree text: NoMedDRA releases: 2024-11 · check-in free text available
- 2022-02-21
- 2022-02-22
- 2022-02-23
- 2022-03-04
- 2022-03-09
- 2022-03-17
- 2022-03-23
- 2022-03-30
- 2022-05-18
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-07-31 | Pfizer-BioNTech | No |
| 2 | 2021-08-21 | Pfizer-BioNTech | No |
| 3 | 2022-02-16 | Pfizer-BioNTech | No |
Free text
Release 11 — days 1–6 daily, dose 3
Systemic reaction (other): No
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SRO | No adverse event | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release